Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.63 USD | -2.16% | +5.52% | +190.40% |
Mar. 14 | Lexaria Bioscience Names Nelson Cabatuan as Finance Chief | MT |
Mar. 14 | Lexaria Appoints Nelson Cabatuan as Chief Financial Officer | CI |
Business Summary
Number of employees: 5
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Intellectual Property Licensing
64.9
%
| 0 | 21.4 % | 0 | 64.9 % | +169.06% |
Business-to-business Product
19.5
%
| 0 | 44.4 % | 0 | 19.5 % | -61.07% |
Research & Development
15.6
%
| 0 | 21.5 % | 0 | 15.6 % | -35.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -11.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Vanessa Carle
LAW | General Counsel | - | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
John Docherty
PSD | President | 53 | 15-04-14 |
Director/Board Member | 76 | 15-09-15 | |
Catherine Turkel
BRD | Director/Board Member | 63 | 22-09-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,671,042 | 11,097,355 ( 87.58 %) | 0 | 87.58 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+190.40% | 44.93M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Lexaria Bioscience Corp. - Nasdaq
- Company Lexaria Bioscience Corp.